In Situ Tissue Labeling of Cerebral Amyloid Using HIV-Related Tat Peptide

Area of Science:

• Neuroscience
• Biochemistry
• Drug Delivery

Background:

• The blood-brain barrier (BBB) impedes peptide drug delivery to the brain.
• Cell-penetrating peptides, like the transactivator of transcription (Tat) protein transduction domain, can cross biological membranes.
• Tat has been explored as a brain-penetrant carrier for Alzheimer disease (AD) therapies targeting amyloid-beta (Aβ) deposits.

Purpose of the Study:

• To investigate whether the Tat peptide binds to amyloid deposits in Alzheimer disease (AD) and other forms of amyloidosis.
• To explore the potential mechanism of Tat binding to amyloid deposits.

Main Methods:

• In situ labeling using biotinylated Tat 48-57 peptide.
• Analysis of brain and tissue samples with amyloid deposits (Aβ, prion protein (PrP), immunoglobulin lambda chains).
• Comparison of binding in tissues processed with alcoholic versus formalin fixatives.
• Inhibition assays using protamine pre-incubation with Tat peptide.

Main Results:

• Tat peptide binds to amyloid deposits composed of Aβ, PrP, and immunoglobulin lambda chains.
• Binding occurs in tissues fixed with alcoholic fixatives but not with formalin.
• Tat peptide binding is inhibited by pre-incubation with protamine, suggesting a role for heparan sulfate glycosaminoglycans (HSGs).
• Tat peptide appears to bind to HSGs present in amyloid deposits.

Conclusions:

• Tat peptide binds to various types of amyloid deposits, likely via HSGs.
• This binding interaction must be considered when using Tat as a brain-penetrant compound for cerebral amyloidoses.
• Tat peptide may serve as a valuable tool for studying amyloidogenesis mechanisms and peptide-GAG interactions.